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ABSTRACT 
As the baby boomer generation continues to age, the diagnosis of osteoporosis and its side 
effects will continue to increase. Denosumab and bisphosphonates (BPs) are some of the most 
common medication classes used to treat osteopenia and osteoporosis, but it is believed that both 
medications have the possible side effect of medication-related osteonecrosis of the jaw 
(MRONJ). The purpose of this paper is to uncover if MRONJ is a side effect of osteoporosis 
treatment and which medication carries the highest incidence rate. Through a review of several 
electronic databases and several peer reviewed research articles, a wide range of reported 
incidence rates of MRONJ for both medications were uncovered, along with many compounding 
possible risk factors. There is the wide range of reported incidence rates among different studies. 
Through the research, it is found that denosumab carries a slightly higher risk of MRONJ versus 
bisphosphonates, but the difference was found to be statistically insignificant. Founded risk 
factors include increasing age, gender, recent dental procedures, history of oral disease, and 
corticosteroid use. My research is impactful in the fact that as providers, we can be better 
informed about the differences between denosumab and bisphosphonates and the possible risk 
factors of MRONJ. We can use the information, along with possible other risk factors and our 
patient’s history, to make joint decisions about what osteoporosis medication is right for our 
patients.  
Keywords: osteonecrosis, jaw, medication-related, bisphosphonates side effects, 
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INTRODUCTION 
The world’s population is ageing: virtually every country in the world is experiencing 
growth in the number and proportion of older persons in their population, and the United States 
is no exception. Two factors—longer life spans and aging baby boomers—will combine to 
double the population of Americans aged 65 years and older during the next 25 years to about 72 
million (CDC, 2013). By 2030, older adults will account for roughly 20% of the U.S. population, 
up from almost 14 percent in 2012 (CDC, 2013). This will have a significant impact on health 
care the age-related medical issues of aging; a loss of bone mineralization and bone mass in the 
forms of osteopenia and osteoporosis being a major issue. By definition from the World Health 
Organization (WHO), osteopenia is defined as a T-score of -1 to -2.5 measured by bone 
densitometry, while a score of less than -2.5 is diagnosed as osteoporosis. In other words, 
osteopenia is caused by a loss of bone density, with osteoporosis being a more severe condition. 
The United States Preventive Services Task Force (USPSTF) has a B grade recommendation for 
screening of osteopenia and osteoporosis via bone densitometry scan in women 65 years and 
older and in younger women whose fracture risk is equal to or greater than that of a 65-year old 
woman who have no additional risk factors (USPSTF, 2016). A grade B recommendation 
equates that the USPSTF recommends the service and that there is a high certainty that the net 
benefit is moderate compared to the risks.  There is insufficient evidence to assess the balance of 
benefits and harms of screening in men (USPSTF, 2016). 
Postmenopausal women are at greatest risk of developing osteoporosis due to accelerated 
loss in bone mass associated with the first several years of menopause (International 
Osteoporosis Foundation, 2017). 200 million women are affected worldwide, with incidence 
rates increasing with age (International Osteoporosis Foundation, 2017). According to the 
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International Osteoporosis foundation, worldwide osteoporosis causes more than 8.9 million 
fractures annually, resulting in an osteoporotic fracture every three seconds (International 
Osteoporosis Foundation, 2017). 24.5% of women and 5.1% of men aged 65 years and over with 
osteoporosis will experience a fracture of the femur or lumbar spine, according to the CDC 
(CDC, 2013). As the average life expectancy continues to increase, the frequency of developing 
fractures and costs associated with the disease are expected to more than double by 2026 
(International Osteoporosis Foundation, 2017). 
In addition to the personal burden and impact on quality of life, the costs associated with 
fracture treatment and rehabilitation are enormous. In Europe, the disability due to osteoporosis 
is greater than the causes by cancers, with the exception of lung cancer, and the lifetime cost is 
comparable or greater than many chronic diseases, such as asthma or high blood pressure 
(International Osteoporosis Foundation, 2017). A study from 2002 estimated national health care 
expenditures attributed to osteoporosis fractures for people aged 45 years and older to be about 
$12 billion annually, with approximately 75% of the costs attributed for direct medical care 
associated with inpatient services, nursing home care, and outpatient services (Desai, Duncan, 
Sloan, 2003). 
There are many different pharmacologic and non-pharmacologic treatment approaches to 
osteoporosis. Denosumab and BPs are two of the most common pharmacologic treatments 
prescribed for osteoporosis. However, both are not without their various side effects. Both 
medications have a possible side effect of osteonecrosis of the jaw, but in family practice, this is 
believed to be very rare. Through a literature review, I seek to answer the question of which 
medication class has the lowest incidence rate of osteonecrosis of the jaw as a side effect of the 
treatment for osteoporosis. 
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Statement of the Problem 
 There are many different approaches to treating osteoporosis. Denosumab and 
bisphosphonates are two of the most common pharmacologic treatments prescribed. However, 
both are not without their various side effects. Both medications are believed to have the possible 
side effect of osteonecrosis of the jaw, but this is believed to be very rare. 
Statement of the Research Questions 
Is the incidence rate of MRONJ greater in those patients treated with denosumab or 
bisphosphonates? Are there any precipitating factors or conditions that increases incidence rates 
of MRONJ with treatment of denosumab or bisphosphonates? 
 
REVIEW OF LITERATURE 
A comprehensive search was performed using several electronic databases, including 
CINAHL, PubMed, Clinical Key, and DynaMed Plus. Specific search keywords included: 
osteonecrosis, jaw, medication-related, bisphosphonates side effects, denosumab side effects, 
abnormal fracture, osteoporosis. A review of the literature yielded several high-quality reviews 
of randomized controlled trials, prospective cohort studies, and case control studies with clinical 
ascertainment of MRONJ. Studies were limited to those with the highest levels of evidence, 
those published after 2008, and to those with the highest level of evidence. Some articles were 
used to provide background information on pathophysiology of osteonecrosis of the jaw (ONJ). 
Several studies were excluded as they compared MRONJ in patients given the medications 
solely for cancer treatment, not for treatment of osteoporosis. 
The drawback to many of the studies is the inconsistencies of the different study 
conditions, including length of treatment, age of patients, and varied sample sizes. Many studies 
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reported incidence rates, but did not state any other conditions of the studies. As the authors 
reported in the Journal of Oral and Maxillofacial Surgeons in 2014, the studies compared had 
sample sizes varying from 233 participants to 90,000 (see figure three). 
Background information of bone physiology:  
Osteopenia and osteoporosis are gradual processes, with many compounding contributing 
factors. The basic pathophysiology of bone loss is due to normal age-related changes in bone 
remodeling, as well as extrinsic and intrinsic factors that exaggerate this process. After age 30 to 
45, the resorption and formation processes become imbalanced, and bone resorption exceeds 
formation (Lindsay & Cosman, 2014). This imbalance may begin at different ages and varies at 
different skeletal sites. Excessive bone loss can be due to an increase in osteoclastic activity 
and/or a decrease in osteoblastic activity. Increased number of bone remodeling site produces a 
reduction in bone tissue, and can result in permanent loss of tissue and disordered skeletal 
architecture. In cortical bone, increased remodeling creates more porous bone with decreased 
overall strength.  
The imbalance between bone resorption and remodeling becomes more exaggerated in 
women after menopause. Estrogen deficiency is believed to cause bone loss by activation of new 
bone remodeling sites that exaggerates the imbalance between bone formation and resorption 
The belief of the importance of estrogen for bone formation and strength is consistent with the 
most osteoporosis cases occurring in post-menopausal women, when a naturally steady decline 
in the amount of estrogen occurs (Lindsay & Cosman, 2014). 
Many factors can increase the process of bone loss. Inadequate calcium during growth 
may impair peak bone mass. During adulthood, insufficient calcium intake contributes to relative 
secondary hyperparathyroidism and increases the rate of bone resorption to maintain normal 
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serum calcium levels. Vitamin D deficiency can also lead to compensatory secondary 
hyperparathyroidism and is an important risk factor for osteoporosis, leading to increased bone 
resorption inactivity can also result in significant bone loss. A large number of medications are 
potentially detrimental to bone strength, with the most common cause being glucocorticoids. The 
use of cigarettes over a significant period can also affect bone moss, both directly by its toxic 
effects or indirectly by modifying estrogen metabolism (Lindsay & Cosman, 2014). 
MRONJ definition: 
In 2003, Marx reported the first cases of what now become known as MRONJ (Coropiuc 
et al., 2017). Initially, osteonecrosis was reported only after treatment with bisphosphonates and 
was referred to as bisphosphonate-related osteonecrosis of the jaw (BRONJ). As other 
antiresorptive classes, like denosumab, seemed to lead to the same outcome, the term was soon 
altered to antiresorptive-related osteonecrosis of the jaw (ARONJ). Since 2014, the American 
Association of Oral and Maxillofacial Surgeons (AAOMS) has recommended the use of the term 
“medication-related osteonecrosis of the jaw” (MRONJ). This change is to better accommodate 
the growing number of cases of osteonecrosis that are associated with other anti-resorptives in 
patients who have not used bisphosphonates previously (Coropiuc et al., 2017). 
 To distinguish MRONJ from other delayed healing conditions and address evolving 
clinical observations and concerns about under-reporting of disease, the working definition of 
MRONJ has been modified from the 2009 AAOMS position paper (Ruggiero et al., 2014).  
Patients are considered to have MRONJ if all the following characteristics are present:  
• Current or previous treatment with antiresorptive or antiangiogenic agents  
• Exposed bone or bone that can be probed through an intraoral or extraoral fistula in the 
maxillofacial region that has persisted for longer than 8 weeks  
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• No history of radiation therapy to the jaws or obvious metastatic disease to the jaws  
ONJ has three intensity stages, determined by the patient’s symptoms and defects of the 
oral mucosa with bone exposure. But different agencies have different concepts on each 
stage criteria (see table one below)  
 
Table 1: Different ONJ staging systems 
Note. Adapted from “Medication-related osteonecrosis of the jaw in oncological patients with 
skeletal metastases,” by R. Coropciuc, K. Grisar, T. Aerden, M. Schol, J. Schoenaers, and C. 
Politis, 2017, British Journal of Oral and Maxillofacial Surgery, 55, p. 787-792. Copyright 
British Association of Oral and Maxillofacial Surgeons 
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Mode of action of denosumab and bisphosphonates: 
 There are two main pharmacological approaches to osteoporosis: anabolic therapy, which 
stimulates new bone formation; and anticatabolic or antiresorptive therapy, which decreases bone 
resorption and/or inhibits bone turnover. Of the antiresorptive therapies, BPs are the most widely 
used for patients with osteoporosis. All BPs directly suppress resorption by inhibiting osteoclast 
attachment and enhancing programmed cell death. Those osteoclasts that do survive have 
reduced resorptive activity. The three most common first-line BPs are alendronate, risedronate, 
and zoledronic acid. All treatments are nitrogen-containing, which target a specific metabolic 
enzyme, farnesyl pyrophosphate synthase (FPPS), which prevents the normal development 
proteins required for osteoclast function and survival (Hanley, Adachi, Bell & Brown, 2012). 
 Denosumab is one of the newest antiresorptive agents. It was the first FDA-approved 
biologic for the treatment of osteoporosis in both men and women (De Paula, Black, & Rosen 
2016). Denosumab is a fully human monoclonal antibody to an osteoclast-differentiating 
receptor activator of nuclear factor-kappa B (RANK). The antibody binds directly to RANK 
ligand, which results in activation of hematopoietic cells of the osteoclast lineage, beginning the 
process of bone resorption (De Paula et al., 2016). By blocking this activation, denosumab 
inhibits osteoclast recruitment and maturation, slowing bone resorption. (Hanley et al., 2012). As 
a result, the medication increases bone mass density, and hence reduces the risk of fracture. 
Unlike BPs, denosumab does not persist in the skeleton long-term and needs to be administered 
once every six months to maintain efficacy. In fact, discontinuation of denosumab can lead to a 
rebound increase in bone resorption (De Paula et al., 2016). 
One major difference between the two medication classes is the length of time the 
medication is taken. It is suggested that patients taking BPs for approximately five years 
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discontinue therapy as there appears to be residual bone density and fracture benefit, and there is 
no evidence that continuing therapy further increases bone density (Rosen, 2017). Denosumab on 
the other hand can be considered a life-sentence, because once a patient begins treatment, the 
patient’s bone density can rapidly decrease once a dose is missed, so the medication is 
recommended to be continued chronically.  
Other differences between the two medications include indication and cost. The 
indication for denosumab is having a diagnosis of osteoporosis at any location in the body via 
bone density scan. The medication is not to be taken for osteopenia without an osteoporosis 
diagnosis of at least one location in the body. BPs can be taken with for a diagnosis of either 
osteopenia or osteoporosis. Cost could also affect which medication is available to patients. 
Although both medications are usually well covered by insurance, one dose of a common BP 
averages about $200, while one dose of denosumab can cost up to $1,100 (Desai et al., 2003). 
 Incidence rate of ONJ with denosumab and bisphosphonates:  
My research had uncovered a wide variety of reported incidence rates of MRONJ.  
In the osteoporosis patient population, the incidence of MRONJ is estimated to be about 
0.001-0.1%, marginally higher than the incidence rate in the general population at less than 
0.001% (Svejda et al., 2016). 
In patients with osteoporosis exposed to placebo agents, the risk of ONJ rages from 0% to 
0.2% (Dodson, 2014). For those patients taking zoledronate, a BP, the risk for MRONJ is 0.02% 
and approximates to the risk for MRONJ in patients exposed to placebo. For patients treated with 
denosumab, the risk for MRONJ ranges from 0.04% to 0.2% (Dodson, 2014). In 2008, 5.1 
million patients older than 55 years received a prescription for BPs. A recent federal study 
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estimates that the prevalence of BP exposure was seven for every 100 persons in the United 
States who received a prescription for a BP in the outpatient setting (Dodson, 2014).  
In a cross-sectional survey study of more than 13,000 patients, the prevalence of MRONJ 
in those receiving long-term oral BP therapy was reported at 0.1%. Felsenberg and Hoffmeister 
(2014) reported a prevalence of MRONJ among patients treated with BPs for osteoporosis of 
0.0004%, which equates to less than one case per 100,000 patients exposed, based on reports to 
the German Central Registry of Necrosis of the Jaw. In a more recent report, Malden and Lopes 
(2012) derived an incidence report that 0.004% of patients exposed to a BP from 11 cases of 
MRONJ reported in a population of 90,000 people living in southeast Scotland. The advantage of 
these studies is the high population studied. But the other conditions of the studies, including 
demographics of the patients and time frame of the study is unknown. Based on a case-control 
study, the risk of MRONJ was 13.1 times greater among patients exposed to oral BPs than in 
patients without exposure (Dodson, 2014). 
According to DynaMed Plus, the estimated incidence of MRONJ is 0.001%-0.01% in 
patients treated with either oral or IV BP therapy. This is only slightly higher than the 
approximate 0.001% incidence in the general population (DynaMed Plus, 2017). These values 
are hard to access because of no conditions of the studies are listed. 
A systematic review of 92 publications evaluating BP MRONJ found an incidence of up 
to 12% after 36 months of exposure in cancer patients (Khanet et al., 2009). But in patients with 
osteoporosis, the incidence rate was found to be less than one case per 100,000 person-years of 
exposure (Khanet et al., 2009). 
In one of the most recent meta-analysis of five randomized trials of denosumab versus 
bisphosphonates, the studies reviewed used different doses and schedules of administration for 
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denosumab and neither of which prospectively evaluated ONJ as an endpoint. The rate of ONJ 
was again higher with denosumab, but the difference was not statistically significant (1.7 versus 
1.1 percent) (Berenson, Stopeck 2017). 
Authors De Paula, et al., (2016) claim the prevalence of MRONJ is very low when 
bisphosphonates are used in the doses used to treat osteoporosis. When much higher doses are 
used to prevent the skeletal complications of cancer, MRONJ is a substantial concern. However, 
in osteoporosis patients, the prevalence is estimated to be less than one in every 100,000 patients 
exposed to oral or intravenous BPs who are otherwise healthy. 
In another study published in July of 2017, the authors aimed to investigate if switching 
to denosumab from a BP is associated with a higher prevalence rate of MRONJ (Loyson et al., 
2017). 110 patients were sequentially treated with BPs followed by denosumab. The median BP 
treatment time was 16 months and the median denosumab treatment was 13 months. 240 patients 
were in the BPs control group, while 240 patients were included in denosumab control group. 
About 6.7% of the patients developed ONJ during BP therapy, and 10% of patients developed 
ONJ during denosumab therapy. In the sequential group, 15.5% of patients developed ONJ after 
therapy of a BP and then denosumab. The incidence of MRONJ was 1.8%, 6.3%, 4.9%, 5.6%, 
and 3.4%, respectively in the first, second, third, fourth, and fifth year of treatment, an MRONJ 
incidence similar to that of the denosumab control group (Loyson et al., 2017). The authors 
concluded that patients treated for osteoporosis seem to have a slightly higher risk of MRONJ 
early after switching from BPs to denosumab compared to patients remaining on BPs. However, 
based on the global MRONJ incidence rates, the switch from BPs to denosumab can be 
considered as safe as initially starting denosumab therapy (Loyson et al., 2017). This study gave 
the some of the best details found regarding the conditions of the study. The drawback of this 
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study is the smaller sample size used as well as the congruency of the medications given after 
each other, making it difficult to assess which medication, or a combination of both, were 
responsible for the MRONJ.  
In 2007, a literature review was performed to clarify the relationship between BP use and 
development of MRONJ for the treatment of osteoporosis. 11 publications from 1966 to 2006 
reporting 26 cases of ONJ in patients being treated with BPs were included. (Pazianas, Miller, 
Blumental, Bernal, & Kothawala, 2007). This was one of the lengthiest literature reviews found 
that was included information of over nearly 40 years. The incidence rate was not reported by the 
authors. However, they did conclude that considering that millions of patients are prescribed 
BPs, the relative prevalence of MRONJ in these patients was low (Pazianas et al., 2007). It was 
not possible for the authors to draw any further conclusions about the associated between BP use 
and MRONJ in these identified studies because of incomplete reporting and the presence of 
compounding factors (Pazianas et al., 2007). Without any other statistics reported, it is also 
difficult for me to access the quality of this study. 
In 2016, several authors conducted a longitudinal study of cases of MRONJ associated 
with denosumab and BPs. The incidence of MRONJ in subjects with osteoporosis was estimated 
at 0.001-0.01%.  MRONJ was more common when BPs were taken intravenously than when 
they were taken orally, with between 2% and 9% of patients showing MRONJ with IV BP and 
0.00001% patients with oral BP (Bagan et al., 2016).  
During my research, I also consulted with Emily Huntley, Physician Assistant of 
rheumatology (EH PA-C) at Rapid City Medical Center. She has more than 13 years of clinical 
experience and has contact with osteoporosis patients on a daily basis. She is also very familiar 
with denosumab and BPs prescribed to treat osteoporosis. In her opinion, she believes the 
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rheumatology community is still “skeptical” regarding the reported side effect MRONJ of BPs 
and denosumab. She states that the medications are often “blamed” as the reason behind this side 
effect, but there are so many other variables and factors that compound the problem, and the 
medications are often “over-attributed” to the development MRONJ. She herself has not seen a 
case of MRONJ. EH PA-C has done research on the medications and has attended conferences 
by the International Endocrinology Society. It is understood that BPs slightly increase a patient’s 
chance of MRONJ, but not denosumab. This is somewhat contradictory to what my research has 
uncovered. EH PA-C believes that because denosumab is a newer class of medication, it has not 
been as studied in long term studies compared to BPs that have been around for years. It is 
understood by the professional endocrinology community that without any treatment, 
0.6/100,000 people will develop ONJ, while on BP therapy, 1/100,000 patients will (personal 
communication, November 29, 2017). So, the risk is very slightly increased by 0.0000094%. 
Other stats are also difficult to interpret because many patients have been on BPs for about three 
to five years as recommended, prior to switching denosumab therapy. So, if a patient develops 
MRONJ, it is hard to determine what medication is specifically to blame. 
 
Table 2: Osteonecrosis of the jaw risk (cases per 10,000 patients) 
Note. Adapted from “Medication-related osteonecrosis of the jaw in oncological patients with 
skeletal metastases,” by R. Coropciuc, K. Grisar, T. Aerden, M. Schol, J. Schoenaers, and C. 
Politis, 2017, British Journal of Oral and Maxillofacial Surgery, 55, p. 787-792. Copyright British 
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Malignancy        
Guarneri et al 
(2010) 
    0.2% (1076) 0.9% (233) Systemic 
review 
Qi et al (2013) 0% 
(1450) 
1.1% (2928)  1.9% (4585)   Systemic 
review 
Scagliotti et al 
(2012) 
 0.8% (400)  0.7% (411)   RCT 




0.7% (1665)     RCT 
Vahtsevanos et al 
(2009) 
 6.7% (1163)     Prospective 
cohort study 




0.33% (3987)     Systemic 
review 
Osteoporosis        




  0.04% 
(4549) 
  RCT 








  0.004% 
(90000) 
   Prospective 
cohort study 
Lo et al (2010)   0.1% 
(8572) 
   Cross-
sectional 
Note.  Sample size in parenthesis 
Adapted from “Medication-Related Osteonecrosis of the Jaw” by S. Ruggiero, T. Dodson, J. 
Fantasia, R. Goodday, T. Aghallo, B. Mehrota, and F. O’Ryan, 2014, Journal of Oral and 




Table 4: Risk of MRONJ among various studies 
 
Authors, Year Placebo Zolendronate Oral BP Denosumab  Study design 
Sugimoto et al., 2014    0.1% (775) RCT 
Bone et al., 2013     RCT 
Long-term exposure group 
(6yr) 
   0.2% (2342) -- 
Short-term exposure group 
(2yr) 
   0.1% (2207) -- 
Papapoulos et al., 2012 0% (3383)   0.04% (4549) RCT 
Grbic et al., 2010 0.02% 
(4945) 
0.02% (5864)   Systematic review 
Malden and Lopes, 2012   0.004% 
(90000) 
 Prospective cohort 
study 
Lo et al., 2010   0.1% (8572)  Cross-sectional 
Note. Adapted from “The frequency of medication-related osteonecrosis of the jaw and its 
associated risk factors,” by T. Dodson, 2014, Oral Maxillofacial Surgical Clinics of North 
America, 27 pg 509-516. Copyright 2015 by American Association of Oral and Maxillofacial 
Surgeons 
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In summary, several studies have reported a slightly higher rate of MRONJ with 
denosumab compared to BPs, but the differences have been reported as not statistically 
significant (Berenson, Stopeck 2017). However, EH PA-C states that bisphosphonates carry the 
higher risk (personal communication, November 29, 2017). This contradiction his is not 
surprising as the reported rates vary greatly from study to study, so it is difficult to come to a 
definitive conclusion between the two medication classes. Moreover, the risk of MRONJ in 
osteoporotic patients receiving antiresorptive therapy continues to be very low regardless of drug 
type (BPs, denosumab) or dosing schedule (Ruggiero et al., 2014). 
Contributing factors of MRONJ: 
Cancer treatment: According to Bagan et al., the incidence of MRONJ is greater in 
patients with cancer due to the higher doses of medications. Corresponding to a wide variety of 
reported incidence rates of MRONJ caused by BPs or denosumab for the treatment of 
osteoporosis, the incidence rates of MRONJ in cancer patients also varies greatly.  
The risk of MRONJ in patients with cancer is about 50 times higher than the risk in 
patients with cancer exposed to placebo (Dodson, 2014), while another source reports the risk 
could be up to 100 times higher (Ruggiero, 2014). According to Dodson (2014), when compared 
with osteoporosis patients receiving antiresorptive therapy, the risk of MRONJ in patients with 
cancer managed with oral BPs or denosumab is about ten times greater. 
Authors Svejda et al., (2016) state the incidence of MRONJ is highest in the oncology 
patient population and report a wide range of cases at 1-15% of patients. Among patients with 
cancer exposed to intravenous BPs, MRONJ risk ranged from 0% to 6.7% in one study (Dodson, 
2014), while another source cited a range of 0.7% to 1.9% (Bagan et al., 2016). Another study 
reports the risk of ONJ among patients with cancer exposed to an oral BP to be 0.7% in a sample 
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of 704 patients (Dodson, 2014). This study is the only one with a listed sample size, so the 
validity of the all of the data is uncertain.  
The majority of studies suggest that the best estimate of MRONJ among patients with 
cancer exposed to IV BPs is in the low single digit percentages ranging from 1-3%. But again, 
most of the study conditions are unknown, which is a significant drawback. 
 In a review study conducted in 2016, the authors aimed to perform a systematic review of 
the relation between treatment with denosumab and the incidence of MRONJ among cancer 
patients. A total of 8963 patients with a variety of solid tumors were included. The overall 
incidence of MRONJ receiving denosumab was 1.7%. The use of denosumab was associated 
with a significantly increased risk of MRONJ in comparison with the placebo control group. The 
authors concluded that denosumab combined with other risk factors including cancer treatment, 
favor the development of MRONJ (Boquete-Castro, Gomez-Moreno, Calvo, Aquilar, & 
Delgado, 2016). The strength of study is significant because of more complete reporting of the 
study conditions and large sample size. 
Form given: MRONJ was more common when BPs were taken intravenously than when 
they were taken orally, with between 2% and 9% of patients showing MRONJ with IV BP and 
1/100,000 patient with oral BP (Bagan et al., 2016). 
Duration of medication therapy as a risk factor: Regardless of indications for therapy, 
the duration of BP or antiresorptive therapy is a significant risk factor for developing MRONJ. 
According to Berenson & Stopeck in Up to Date (2017), the incidence is higher with longer 
duration of treatment, particularly when the duration of therapy exceeds four years. The onset of 
MRONJ may be shortened by the presence of other comorbidities. In a retrospective series of 
3994 patients who received IV bisphosphonates, the median duration of pamidronate, a BP, was 
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longer in those who developed ONJ compared with those who did not: 1.68 versus 0.59 years in 
breast cancer and 1.55 versus 0.3 years in multiple myeloma (Berenson & Stopeck. 2017). The 
same findings were noted among patients receiving zoledronic acid, a BP: 2.04 versus 0.73 years 
in breast cancer, and 1.85 versus 0.67 years in myeloma. In another study, the cumulative hazard 
of developing MRONJ increased according to the duration of IV bisphosphonate therapy: 0 
percent at one year to 11 percent at four years. (Berenson & Stopeck, 2017). In patients with 
cancer exposed to zoledronate or denosumab, the incidence of developing ONJ was 0.6% or 
0.5% after one year of taking the medication, 0.9% or 1.1% after two years, and 1.3% or 1.1% 
after three years, respectively (Ruggiero et al., 2014). The same statistics are quoted by Dodson, 
2015.  The risk for developing MONJ in patients taking denosumab plateaued around two or 
three years (Ruggiero et al., 2014). This data is very valid due to complete reporting and direct 
comparison of the different treatments. The data is strengthened more by the same statistics 
reported by two different sources. 
In a study by Saad et al., (2014) the investigators combined three blinded phase trials and 
found similar results, including a plateau of incidence rate after two years for patients exposed to 
denosumab. In patients with cancer exposed to zoledronate or denosumab (n = 5,723), the 
incidence of developing ONJ was 0.5% or 0.8% after one year, 1.0% or 1.8% at two years, and 
1.3% or 1.8% at three years, respectively. For patients receiving oral BP therapy to manage 
osteoporosis, the prevalence of MONJ increases over time, from nearly 0% at baseline to 0.21% 
after at least four years of BP exposure (Ruggiero et al., 2014).  
Authors Fleisheret et al., published a review in 2013 of a retrospective cohort study of 
patients to identify the onset of ONJ based on the exposure to BP therapy and associated triggers 
based on the route of BP administration. The records of 114 patients with a history of ONJ were 
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reviewed and divided into cohorts by the route of BP administration, with 76 patients having a 
history of IV BP therapy and 38 patients using oral BP treatment. The overall onset of MRONJ 
was earlier in the IV BP group, with a median onset of three years. The median onset in the oral 
BP group was five years. The authors concluded the median onset of ONJ for patients 
undergoing IV BP therapy occurs earlier than the median onset for patients undergoing oral BP 
therapy (Fleisher et al., 2013). However, the small sample size is a limiting factor to this study. 
Another found that in patients receiving oral BP therapy to manage osteoporosis, the 
prevalence of ONJ increases over time from year zero at baseline to 0.2% after four or more 
years of BP treatment. After two years of treatment with denosumab, the incidence of MRONJ in 
patients was 0.09% and then nearly doubled to 0.2% after six years (Dodson, 2015). 
Local factors: 
Operative treatment: Patients who undergo dental procedures that invade bone, such as 
tooth implantation and tooth extraction, are at increased risk of MRONJ (De Paula, Black, & 
Rosen, 2016). Several studies have reported that in patients with MRONJ, tooth extraction is a 
common predisposing event, with 52 to 61% of patients reporting tooth extraction as the 
precipitating event (Ruggiero et al., 2014). In a case-control study of cancer patients exposed to 
zoledronate, tooth extraction was associated with a 16-fold increased risk of MRONJ when 
compared with counterparts without MRONJ (OR: 16.4, CI: 95%). The best estimate for the risk 
of developing MRONJ after tooth extraction or other dentialveolar procedures in patients 
exposed to oral BPs is 0.5% (Ruggiero et al., 2014). This was the one of the only studies found 
that reported a confidence interval. But a drawback of this study is that it was done in cancer 
patients not in osteoporosis patients, so the patient population varies from the intended 
population group, which could highly influence the significance of the results. 
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However, in a study by Fleisheret et al., (2013), there was no difference found in rate of 
MRONJ occurring spontaneously or after dental extraction. The lack of evidence suggesting 
greater onset after dental extraction may provide clinical support for dentialveolar surgery that is 
indicated for patients with a history of BP therapy (Fleisher et al., 2013). This study has more 
validity to my research as the study observed osteoporosis patient instead of those undergoing 
cancer treatment. 
Concomitant oral disease: Pre-existing inflammatory dental disease, such as periodontal 
disease, is a well-recognized risk factor for developing MRONJ (Ruggiero et al., 2014). Given 
that a common treatment of inflammatory dental disease is tooth extraction, pre-existing dental 
disease may compound the correlation between tooth extraction and the risk for MRONJ. 
According to EH PA-C, it can be a tricky attempting to treat osteoporosis in patients with 
oral disease of any kind. In this situation, we as providers have to be able to weigh the benefits of 
treating versus the possible risks of treating.  
Demographic, systemic, and other medication factors: Age and gender are variably 
reported as risk factors for MRONJ. The higher prevalence in the female population is likely a 
reflection of the underlying disease for which the agents are being prescribed, i.e., osteoporosis 
(Ruggiero et al., 2014). There is very limited data describing the occurrence of MRONJ in the 
pediatric population, as denosumab or BPs are very rarely prescribed to pediatric patients.  
 Corticosteroids are associated with an increased risk of MRONJ as they can further 
weaken bones (Ruggiero et al., 2014). Bone loss occurs soon after corticosteroid therapy is 
initiated and results from a complex mechanism involving osteoblastic suppression and increased 
bone resorption. When high doses of prednisolone greater than 20 mg/day or equivalent are used, 
the annual rate of loss of spinal bone density is 5-15% (Romas, 2008). The rate of bone loss is 
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most marked in the first six months after starting corticosteroids and can be as high as 27% 
(Romas, 2008). In contrast to premenopausal women, people over 50 years of age and 
postmenopausal women are more susceptible to osteoporosis, even with lower corticosteroid 
doses (Romas, 2008). Any condition that further decreases a person’s bone density increases 
their chance of MRONJ, especially in this subset of patients that are already at risk of 
osteoporosis. 
 Tobacco use has been inconsistently reported as a risk factor for MRONJ. In a case-
control study in 2012, tobacco use approached statistical significance as a risk factor for ONJ in 
patients with cancer (OR = 3.0; 95% CI, 0.8-10.4) (Ruggiero et al., 2014). In a more recent case-
controlled studies, the authors were unable to find an association between tobacco use and 
MRONJ (Ruggiero et al., 2014). 
Genetic factors: There have been several reports describing single nucleotide 
polymorphisms (SNPs) that have been associated with developing MRONJ. Most of these SNPs 
are located within regions of the gene associated with bone turnover, collagen formation, or 
certain metabolic bone diseases. In one study, an ONJ event rate of 57% was reported when 
SNPs were present in five candidate genes that were responsible for bone turnover. In a genome 
wide study, it was reported that patients with an SNP in a specific gene associated with bone 
density and collagen formation, were 5.8 times more likely to develop MRONJ. In a study that 
analyzed polymorphisms related to farnesyl diphosphate synthase, an enzyme specifically 
inhibited by BPs, a positive correlation was established with the carrier status and MRONJ 
(Ruggiero et al., 2014). Collectively, these studies suggest a likely genetic link between MRONJ 
and BP therapy.  
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According to EH PA-C, if patient has a family history of ONJ, she would potentially not 
recommend osteoporosis treatment in the form of BPs or denosumab. In our conversation, we 
discussed a hypothetical situation in which if a mother developed MRONJ, would she as a 
provider reconsider not initiating osteoporosis treatment in the form of a BP or denosumab for 
the daughter. She would potentially not start therapy in this situation, as the patient may have an 
increased risk of developing MRONJ. She would however, have an educational conversation 
with the daughter as a patient and highly recommended good dental hygiene and regular dental 
exams if the patient would choose to start therapy. A family history would not stop EH PA-C 
from starting osteoporosis therapy, but she would make sure the patient was well-informed and 
educated about the possible increased risk of complications. (personal communication, 
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DISCUSSION  
 The pathophysiology of MRONJ is complex and multifactorial. This paper sought to 
answer the questions: is the incidence rate of MRONJ greater in those patients treated with 
denosumab or bisphosphonates? And are there any precipitating factors or conditions that 
increases incidence rates of MRONJ with treatment of denosumab or bisphosphonates? Upon 
review of multiple studies, there are numerous statistical ranges and prevalence rates reported by 
numerous associations in different settings and demographics. 
 
Is the incidence rate of MRONJ greater in those patients treated with denosumab or 
bisphosphonates? 
 Among the different studies, the prevalence rate of MRONJ with BP therapy ranged 
greatly between 0.0004-9%, and the rate with denosumab varied as well from 0.04-0.2%. One 
study reported a slightly higher risk after switching from a BP to a denosumab, from 6.7% to 
10% (Loyson et al., 2017). One study found that the rate of MRONJ was also higher with 
denosumab, but authors concluded the difference was not statistically significant, as the 
difference was 1.7% versus 1.1% (Berenson & Stopeck, 2017). However, these studies used 
different doses and schedules of administration, so the varying conditions make it difficult to 
compare the results with full confidence. Many studies were unable to draw conclusions based 
on the minor differences in statistics, and it is common theme for them to conclude that the 
relative prevalence of MRONJ among patients is low.  
According to EH PA-C, BPs cause MRONJ while denosumab does not (personal 
communication, November 29, 2017).  This is somewhat contradictory to some research I have 
found, but reiterates the idea that it is very difficult to make a forgone conclusion between the 
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two medications. It is reasonable to think that because denosumab is a newer medication, it is not 
studied as well as BPs, which have been around for numerous years, and it may be possible for 
the known risk of MRONJ with denosumab to increase as the studies increase. 
During my research, it was found to be rather difficult to find studies that solely 
compared BP with denosumab under the same conditions. Many studies used small and varying 
sample sizes, not all studies used control groups, and the lengths of the studies varied or were not 
reported. Also, many of the studies compared the rates of MRONJ after treatment of one 
medication and then the other. In this situation, it can be near impossible to say with complete 
confidence which medication is responsible for the MRONJ, or whether there is a compound 
effect of the two medications when used consecutively.  
In the general population, it can also be difficult to identify the medication to blame, 
because of the common practice of how and when these medications are prescribed. In most 
cases, the osteoporosic patient is prescribed BP therapy for about five years until the therapeutic 
effect is maximized, and then often the patient is switched to denosumab or another class of 
medication to be used chronically. This transitioning to different medications can make it 
difficult to pinpoint the specific medication to blame if MRONJ develops. This is consistent with 
the information that I received during my interview with EH PA-C as well.  
 Also, during my search, I found many cases that compared the prevalence rate of 
MRONJ in patients with varying comorbidities. This variance makes it not possible to draw 
further conclusions about the potential associated between bisphosphonates use and MRONJ in 
identified studies because of incomplete reporting and the presence of confounding factors. 
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Are there any precipitating factors or conditions that increases incidence rates of MRONJ 
with treatment of denosumab or bisphosphonates? 
 Denosumab and BPs are often used as treatment for some cancers that can cause bone 
damage. The medications are used in higher doses compared to those used for osteoporosis. 
Cancer can greatly increase a patient’s risk for MRONJ, but again the prevalence rates reported 
vary greatly from 1-15% and up to 50-100 times higher than a patient in the control group. This 
is logical, as a patient would have a greater chance of jaw bone necrosis if there is previously 
compromised bone strength due to cancer. 
 There are many different comorbidities that greatly increase the patient’s chance of 
MRONJ. One of the greatest risk factors is dental procedures. One study found that in patients 
with MRONJ, 52-61% reported a history of tooth extraction (Ruggiero et al., 2014). However, a 
different study found no difference in MRONJ onset after tooth extraction (Fleisheret et al., 
2013).  
 Age and gender are variably reported as risk factors. A higher prevalence rate is 
consistent with the population of patients treated for osteoporosis, which is normally aging 
females. Corticosteroid use is also associated with increasing risk, as they can further weaken 
bones (Ruggiero et al., 2014).  Studies including tobacco use shows inconclusive MRONJ 
association. 
 There could also possibly be a genetic link to developing MRONJ. One study reported an 
MRONJ rate of 57% with SNPs present on genes responsible for bone turnover (Ruggiero et al., 
2014). Another study found that patients were 5.8 times more likely to develop MRONJ with an 
SNP in a specific gene that is associated with bone density and collagen formation (Ruggiero et 
al., 2014).  
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 Although there are several risk factors to developing MRONJ, EH PA-C stated that not 
all risks are treated equally, and not all risk factors should prevent us as providers from halting 
therapy (personal communication, November 29, 2017).  We as providers need to weigh the 
benefits versus risks for all the risk factor and base our decisions to treat with each individual 
patient in mind. 
In summary, my research is mostly inconclusive. While a few source states a higher 
incidence rate of denosumab, most have inconclusive results or are unable to draw a conclusion. 
The wide ranges of reported prevalence rates of MRONJ in different studies under different 
conditions makes it extremely difficult to determine what class of medications, BPs or 
denosumab, causes the higher prevalence rate of MRONJ. I am unable to draw my own 
conclusion about what medication class causes the greatest risk of MRONJ; however, I was able 
to uncover numerous comorbidities and risk factors that would increase the chance of MRONJ. 
Although I was not successful in answering one of my research questions, I believe my research 
was successful as it allows for the acquisition of knowledge and application to future practice. I 
agree with several statements my research uncovered that the risk of MRONJ in osteoporotic 
patients receiving antiresorptive therapy continues to be very low regardless of drug type (BPs, 
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APPLICABILITY TO CLINICAL PRACTICE 
My research was to determine which medication class has the highest prevalence rate of 
MRONJ and to uncover possible the risk factors. So how does this research apply to clinical 
practice? The baby boomer generation in the United States continues to age, and the population 
of Americans aged 65 years or older during the next 25 years is expected to double to about 72 
million (CDC, 2013). In fact, by 2030, older adults are expected to account for roughly 20% of 
the U.S. population (CDC, 2013). During my clinical experiences, I have cared for many elderly 
patients. As potential future family practice providers, a large proportion of our patients will lie 
in this age range, so it is imperative to be aware of common conditions that could affect this 
population. Because of the USPSTF recommendation of bone density scans, many patients will 
have the diagnosis of osteopenia and/or osteoporosis. Both conditions can be debilitating and 
cause significant physical impairment if left untreated, with hip fracture being one of major 
significance. 
Hip fracture in older adults is a leading public health concern. Hip fractures are 
associated with significant increased risk of mortality, loss of independence, and financial 
burden. In one study, the reported one-year mortality after sustaining a hip fracture was 
estimated to be 14% to 58% (Schnellet et al., 2010). A recent meta-analysis revealed that women 
sustaining a hip fracture had a five-fold increase and men almost an eight-fold increase in 
relative likelihood of death within the first three months following the injury as compared with 
age and sex-matched controls (Schnellet et al., 2010). Loss of function and independence among 
survivors is profound, with 40% of patients unable to walk independently and 60% requiring 
assistance one-year post-fracture. (International Osteoporosis Foundation, 2017). Because of 
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these losses, 33% of patients are completely dependent or in a skilled nursing facility in the year 
following a hip fracture (International Osteoporosis Foundation, 2017). 
Because osteoporosis is becoming more and more prevalent as the baby boomers age, it 
is imperative to make every attempt to prevent hip and other fractures. This can be accomplished 
by following the recommended guidelines for bone density scans and by treating osteopenia and 
osteoporosis appropriately. 
There are many different treatment options for osteoporosis, among them BPs and 
denosumab. Both treatments have their associated side effects, and it’s crucial that we are aware 
of the different side effects for each. However, because there are many different classes of 
medications, there is not a one-size-fits-all solution for osteoporosis treatment. In any situation, 
we as providers have to be able to weigh the benefits of treating versus the possible risks of 
treating. We will need to take each patient’s preference and personal medical history in to 
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